Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease

Annals of Oncology

Volumn 7, Issue SUPPL. 4, 1996, Pages

  Hasenclever, D ^a   Loeffler, M ^a   Diehl, V ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Chemotherapy; Dose response relationship; Hodgkin's disease; Randomized clinical trials; Statistical models; Tumour growth kinetics

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG SENSITIVITY; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KINETICS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STATISTICAL MODEL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR GROWTH;

EID: 0029848818     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/7.suppl_4.S95     Document Type: Conference Paper

References (6)

1. Frei E, Canellos GP. Dose: A critical factor in cancer chemotherapy. Am J Med 1980; 69:585-94.
2. Charbit A, Malaise EP, Tubiana M. Relation between the pathological nature and the growth rate of human tumors. Eur J Cancer 1971; 7:307-15.
3. Hasenclever D. Tumorwachstum und Wirkung von Chemotherapie. Dissertation, University of Cologne, Germany 1995.
4. Diehl V. Dose-escalation study for treatment of Hodgkin's disease. The German Hodgkin Study Group. Ann Hematol 1993; 66(3): 139-40.
5. Redmond C, Fisher B, Wieand HS. The methodologie dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. Cancer Treat Rep 1983; 67(6): 519-26.
6. De Vita VT, Hubbard SM, Longo DL. The chemotherapy of lymphomas: Looking back, moving forward - the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1987; 47:5810-24.